NCT04420299

Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19

A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Fundación de investigación HM · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving patients survival and reducing complications in its management, for which many different types of treatments are being tested. The drug being tested in this clinical trial is called bemiparin. Bemiparin is a drug authorized as a prevention and as a treatment for deep vein thrombosis (blood clots in one or more veins, generally in the legs) and venous thromboembolism (when the clot can detach and lodge in other organs such as the lungs). Covid-19 patients have been shown to be at increased risk of developing clotting problems such as those described above. In this context, this clinical trial is being carried out to find out if certain doses of bemiparin can contribute to better management of the disease.

Conditions

• Covid-19

Interventions

Type	Name	Description
DRUG	Bemiparin	Bemiparin at therapeutic dose for 10 days
DRUG	Bemiparin	Bemiparin at prophylactic dose for 10 days

Timeline

• Start date: 2020-06-04
• Primary completion: 2021-06-08
• Completion: 2021-06-08
• First posted: 2020-06-09
• Last updated: 2022-06-07

Locations

2 sites across 1 country: Spain